Theravance Biopharma, Inc. - Ordinary Shares (TBPH) News
Filter TBPH News Items
TBPH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TBPH News Highlights
- TBPH's 30 day story count now stands at 18.
- Over the past 21 days, the trend for TBPH's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- BEAT, BIO and GSK are the most mentioned tickers in articles about TBPH.
Latest TBPH News From Around the Web
Below are the latest news stories about Theravance Biopharma Inc that investors may wish to consider to help them evaluate TBPH as an investment opportunity.
Theravance Biopharma's (TBPH) CEO Rick Winningham on Q4 2021 Results - Earnings Call TranscriptTheravance Biopharma, Inc. (TBPH) Q4 2021 Earnings Conference Call February 23, 2022 5:00 PM ET Company Participants Gail Cohen – Vice President-Corporate Communications Rick Winningham – Chief Executive Officer Rhonda Farnum – Senior Vice President, Commercial and Medical Affairs Rick Graham – Senior Vice President, Research and Development Andrew Hindman... |
Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue EstimatesTheravance Bio (TBPH) delivered earnings and revenue surprises of -43.33% and 4.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateTheravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the fourth quarter and full year ended December 31, 2021. |
Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & MoreLet us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23. |
Theravance Biopharma to Participate in an Upcoming Investor ConferenceTheravance Biopharma, Inc. (NASDAQ: TBPH) will participate in the Respiratory/Infections Corporate Panel Discussion at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, at 2:10 pm ET (11:10 am PT/7:10 pm GMT). |
Repligen (RGEN) Q4 Earnings and Revenues Surpass EstimatesRepligen's (RGEN) fourth-quarter earnings and revenues beat estimates. It expects to achieve revenue growth in the range of 19-24% in 2022. |
Wall Street Analysts Think Theravance Bio (TBPH) Could Surge 27%: Read This Before Placing a BetThe mean of analysts' price targets for Theravance Bio (TBPH) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Intellia (NTLA) Up on Deal With ONK for Cancer TherapiesIntellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer. |
CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/YCRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates. |
Zoetis' (ZTS) Q4 Earnings and Revenues Surpass EstimatesZoetis' (ZTS) earnings and revenues beat estimates for the fourth quarter of 2021. |